FFP in Spontaneous Subdural Hematoma in Dengue Patients
Fresh frozen plasma is NOT routinely indicated for spontaneous subdural hematoma in dengue patients unless there is documented coagulopathy with INR >1.5 or specific coagulation factor deficiencies, and even then, platelet transfusion and surgical evacuation take priority over FFP. 1
Primary Management Approach
Platelet transfusion is the critical intervention for dengue-related intracranial hemorrhage, not FFP. 2 The pathophysiology of bleeding in dengue is primarily thrombocytopenia-driven, not coagulation factor deficiency. 2, 3
When FFP May Be Considered
FFP should only be administered if ALL of the following criteria are met:
- Active bleeding is present (expanding hematoma or clinical deterioration) 1, 4
- Documented coagulopathy with INR ≥1.5, PT >1.5 times normal, or aPTT >2 times normal 1, 5
- Patient is being prepared for urgent neurosurgical evacuation 1, 4
Specific Dosing if FFP is Indicated
If the above criteria are met, administer 10-15 ml/kg (approximately 700-1050 ml for a 70 kg patient, or 3-4 units) as rapidly as clinically tolerated. 5, 6 Doses below 10 ml/kg are unlikely to achieve the 30% factor concentration threshold needed for hemostasis. 5
Critical Coagulation Parameters to Check
Before considering FFP, obtain:
- Platelet count (primary concern in dengue; transfuse if <50,000/mm³ with active bleeding or <10,000/mm³ prophylactically) 2
- INR/PT and aPTT (FFP only justified if INR >1.5) 1
- Fibrinogen level (if <1.5 g/L, use cryoprecipitate instead of FFP) 1, 5
- Liver enzymes (AST/ALT) (elevated levels are risk factors for bleeding in dengue) 2
Common Pitfalls to Avoid
Do not use FFP to correct laboratory values alone without active bleeding. 1, 5 This is a critical error that exposes patients to unnecessary risks including TRALI, circulatory overload, and infectious transmission. 5
Do not use FFP as a treatment for thrombocytopenia in dengue. 3 While one study showed a transient platelet increase at 12 hours post-FFP infusion, this effect was not sustained at 24-48 hours and is not clinically meaningful. 3 The mechanism of thrombocytopenia in dengue is consumptive and immune-mediated, not factor deficiency. 2
Do not delay neurosurgical consultation while attempting medical reversal. 2 Dengue-related subdural hematomas often require urgent surgical evacuation regardless of coagulation status. 2, 7
Evidence-Based Management Algorithm
Confirm diagnosis: Dengue serology (IgG/IgM, NS1 antigen) plus neuroimaging showing subdural hematoma 2, 7
Assess bleeding severity: Serial CT scans to evaluate hematoma progression 2, 8
Check coagulation profile: Platelet count, INR, PT, aPTT, fibrinogen 2
Primary interventions:
Monitor: Repeat imaging and coagulation studies every 3-6 hours initially 8
Special Considerations for Dengue
Unlike anticoagulant-associated intracranial hemorrhage where FFP has clear indications 1, dengue-related hemorrhage is fundamentally different. The coagulation profile in dengue patients is often normal or only mildly deranged despite severe thrombocytopenia. 2, 7 One case report documented a dengue patient with spontaneous spinal subdural hematoma whose "hemogram, biochemistry, and coagulation profile was within normal limits." 7
Risk factors for bleeding in dengue include: thrombocytopenia, elevated AST/ALT, and positive IgG antibodies (indicating secondary infection). 2 These do not respond to FFP therapy.